ARCELLX INC Stock Price, News & Analysis

Arcellx, Inc. (NASDAQ: ACLX) has appointed Michelle Gilson as the new Chief Financial Officer. Gilson previously served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, specializing in biotechnology. Her extensive background in capital markets will enhance Arcellx's financial strategy as they advance their innovative cell therapies aimed at treating cancer. The lead product candidate, CART-ddBCMA, is in an ongoing Phase 1 study and has received multiple FDA designations, underscoring the company's commitment to developing effective treatment options.

Arcellx, Inc. (NASDAQ: ACLX) announced the appointment of Olivia Ware to its Board of Directors, replacing Lewis T. "Rusty" Williams, M.D. Ware brings over 20 years of experience in biotech and pharmaceutical drug development, having played key roles in launching major oncology drugs such as Rituxan and Herceptin. Her expertise is expected to enhance the company's strategic direction, especially as it prepares for a Phase 2 study of CART-ddBCMA for relapsed or refractory multiple myeloma. The company is focused on advancing innovative immunotherapies and has received multiple FDA designations for its lead product.

Arcellx, Inc. (NASDAQ: ACLX) initiated a Phase 1 clinical trial for ACLX-001 utilizing its innovative ARC-SparX technology to treat relapsed or refractory multiple myeloma (r/r MM). The company raised $142 million in its IPO and reported cash reserves of $210.9 million as of March 31, 2022, sufficient to fund operations into late 2023. Unfortunately, they posted a net loss of $32.4 million with R&D expenses increasing to $24.4 million. Upcoming presentations at the ASCO Annual Meeting are anticipated to provide further insights into their clinical data.

Arcellx, Inc. (NASDAQ: ACLX) has initiated its Phase 1 clinical trial for ACLX-001, targeting relapsed or refractory multiple myeloma (r/r MM). The trial, utilizing the innovative ARC-SparX platform, aims to evaluate safety and tolerability while addressing challenges like dose-limiting toxicities and tumor heterogeneity. The first patient has been dosed, and initial data is expected in 2023. The ARC-SparX technology combines SparX proteins and ARC-T cells to enable controlled and adaptable treatment options, potentially enhancing patient access to CAR-T therapies.

On May 9, 2022, Arcellx, Inc. (ACLX) announced key clinical data for CART-ddBCMA from its ongoing Phase 1 study aimed at treating relapsed or refractory multiple myeloma. Published in Blood Advances, the findings show a 100% overall response rate (ORR) and a 75% complete response/sustained complete response (CR/sCR) in 12 patients. The trial reported no significant adverse effects, solidifying CART-ddBCMA's safety profile. Following these results, Arcellx plans to expand the study and present new data at ASCO on June 5, with a pivotal Phase 2 study expected later in 2022.

Arcellx, Inc. (NASDAQ: ACLX) will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:00 p.m. E.T. The discussion will be accessible via a live webcast on the company's website and will be archived for 30 days. Arcellx focuses on developing advanced immunotherapies for cancer and other diseases, with its lead candidate CART-ddBCMA currently in a Phase 1 study for relapsed or refractory multiple myeloma. The company holds multiple designations from the FDA to expedite its clinical development.

Arcellx, Inc. (NASDAQ: ACLX) announced the upcoming presentation of new clinical data from its Phase 1 Study of CART-ddBCMA for treating relapsed or refractory multiple myeloma at the ASCO Annual Meeting on June 5, 2022. The oral presentation will be delivered by Dr. Matthew J. Frigault from Massachusetts General Cancer Center. The company will also host a live webcast discussing these results on the same day. CART-ddBCMA has received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations from the FDA, underscoring its potential in cell therapy.

Arcellx (ACLX) announced promising preclinical data for ACLX-002, a CD123-targeted universal CAR-T cell therapy aimed at treating relapsed or refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The data show complete regression of multiple AML xenografts, evidencing the therapy's potential effectiveness. The company plans to initiate a Phase 1 clinical trial for ACLX-002 in the second half of 2022. The findings were presented at the AACR Annual Meeting, highlighting the innovative ARC-SparX platform that aims to improve treatment options for patients.

Arcellx, Inc. (NASDAQ: ACLX) raised $142.3 million via its upsized IPO, completed in February 2022, enhancing its ability to advance innovative therapies for cancer. The company reported a net loss of $65 million for 2021, up from $32 million in 2020. R&D expenses rose significantly to $46.9 million for the year, driven by developments in its CART-ddBCMA program. Arcellx plans to progress its CART-ddBCMA program to Phase 2 and initiate two Phase 1 trials in 2022.